Want to see TVGN full AI Analyst Report?
Top Page
Tevogen Bio Holdings
(NASDAQ:TVGN)
Select Model
Select Model
Rating:42Neutral
Price Target:
$6.00
▲(1775.00% Upside)
Action:Reiterated
Date:06/30/26
The score is driven primarily by weak financial performance (no revenue, ongoing losses, negative equity, and sustained cash burn) indicating high financing and dilution risk. A notable additional headwind is the Nasdaq market value compliance issue. Valuation is difficult to support due to negative earnings, and technical signals cannot be assessed due to missing indicators.
Positive Factors
Targeted T‑cell immunotherapies
A focused platform in precision cytotoxic T lymphocyte (CTL) therapies targets persistent structural demand in oncology and infectious disease immunotherapies. A clear scientific niche and platform approach increase the potential for durable clinical value and licensing or partnership opportunities if trials progress successfully.
Negative Factors
No revenue; sustained losses
Absence of revenue and persistent operating and net losses indicate the company remains pre-revenue and dependent on external financing. This structural lack of cash generation increases dilution risk, limits reinvestment ability, and means profitability and margin sustainability depend entirely on successful clinical/commercial milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted T‑cell immunotherapies
A focused platform in precision cytotoxic T lymphocyte (CTL) therapies targets persistent structural demand in oncology and infectious disease immunotherapies. A clear scientific niche and platform approach increase the potential for durable clinical value and licensing or partnership opportunities if trials progress successfully.
Read all positive factors
Tevogen Bio Holdings (TVGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$23.88M
Dividend YieldN/A
Average Volume (3M)557.82K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue GrowthN/A
EPS Growth38.95%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.84
Shares Outstanding4,219,343
10 Day Avg. Volume531,944
30 Day Avg. Volume557,817
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap1.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-299.01
Enterprise Value/Ebitda-2.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.14
Revenue Forecast (FY)N/A
Tevogen Bio Holdings Business Overview & Revenue Model
Company Description
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precisio...
How the Company Makes Money
null...
Tevogen Bio Holdings Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
14
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -144.84K | 0.00 | -403.58K | -378.36K | 0.00 | 0.00 |
| EBITDA | -20.83M | -25.57M | -13.14M | -58.89M | 4.64M | -14.99M |
| Net Income | -21.35M | -26.28M | -10.11M | -60.48M | 4.41M | -15.60M |
Balance Sheet | ||||||
| Total Assets | 4.92M | 4.38M | 3.46M | 5.51M | 7.74M | 7.66M |
| Cash, Cash Equivalents and Short-Term Investments | 692.30K | 552.37K | 1.28M | 1.05M | 5.48M | 7.12M |
| Total Debt | 3.07M | 3.10M | 2.89M | 95.42M | 40.01M | 23.48M |
| Total Liabilities | 14.76M | 12.62M | 10.14M | 99.93M | 41.69M | 24.15M |
| Stockholders Equity | -9.84M | -8.23M | -6.67M | -94.43M | -33.95M | -16.49M |
Cash Flow | ||||||
| Free Cash Flow | -11.82M | -12.39M | -12.00M | -8.30M | -9.13M | -5.38M |
| Operating Cash Flow | -11.75M | -12.33M | -12.00M | -8.17M | -8.66M | -5.27M |
| Investing Cash Flow | -64.44K | -64.44K | 0.00 | -133.00K | -479.04K | -109.73K |
| Financing Cash Flow | 10.54M | 11.66M | 12.23M | 3.87M | 7.50M | 12.50M |
Tevogen Bio Holdings Technical Analysis
Negative
0.32
Price Trends
8.54
Negative
8.59
Negative
17.17
Negative
Market Momentum
0.07
Positive
38.32
Neutral
17.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVGN, the sentiment is Negative. The current price of 0.32 is below the 20-day moving average (MA) of 9.45, below the 50-day MA of 8.54, and below the 200-day MA of 17.17, indicating a bearish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 38.32 is Neutral, neither overbought nor oversold. The STOCH value of 17.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TVGN.
Tevogen Bio Holdings Risk Analysis
Tevogen Bio Holdings disclosed 76 risk factors in its most recent earnings report. Tevogen Bio Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tevogen Bio Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $516.35M | -4.00 | -50.68% | ― | -12.37% | 19.59% | |
58 Neutral | $487.80M | -13.94 | -147.78% | ― | ― | -16.88% | |
52 Neutral | $627.18M | -11.20 | -60.73% | ― | -78.29% | 54.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $202.47M | -2.08 | -30.90% | ― | ― | 10.70% | |
42 Neutral | $23.88M | -0.99 | 241.39% | ― | ― | 38.95% |
* Healthcare Sector Average
TVGN
Tevogen Bio Holdings
5.66
-55.34
-90.72%
NKTX
Nkarta
2.83
1.12
65.50%
CCCC
C4 Therapeutics
4.67
3.16
209.27%
STTK
Shattuck Labs
6.94
6.12
746.34%
NVCT
Nuvectis Pharma
18.39
11.08
151.57%
ACTU
Actuate Therapeutics, Inc.
1.53
-4.60
-75.04%
Tevogen Bio Holdings Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Tevogen Bio Faces Nasdaq Market Value Compliance Challenges
Negative
Apr 22, 2026
On April 16, 2026, Tevogen Bio Holdings Inc. was notified by Nasdaq that it no longer meets the $50 million minimum market value of listed securities required for continued listing on the Nasdaq Global Market, based on the prior 30 consecutive bus...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.